Clinical and Translational Radiation Oncology · 2021 · 27 citations · 21 references
MedicineOncologyRadiation OncologyBiomedical ImagingDiagnostic ImagingUltrasonographyNeck UltrasonographyRadiation TherapyTherapy Response AssessmentTumor CharacterizationTumor ImagingUltrasound In OncologyLeave-one-out Cross-validationQuantitative UltrasoundRadiomic Recurrence PredictionRadiomicsRadiomics PrognosisSequential Forward SelectionTexture FeaturesUltrasound Radiomics
PURPOSE: This study investigated the use of quantitative ultrasound (QUS) obtained during radical radiotherapy (RT) as a radiomics biomarker for predicting recurrence in patients with node-positive head-neck squamous cell carcinoma (HNSCC). METHODS: Fifty-one patients with HNSCC were treated with RT (70 Gy/33 fractions) (±concurrent chemotherapy) were included. QUS Data acquisition involved scanning an index neck node with a clinical ultrasound device. Radiofrequency data were collected before starting RT, and after weeks 1, and 4. From this data, 31 spectral and related-texture features were determined for each time and delta (difference) features were computed. Patients were categorized into two groups based on clinical outcomes (recurrence or non-recurrence). Three machine learning classifiers were used for the development of a radiomics model. Features were selected using a forward sequential selection method and validated using leave-one-out cross-validation. RESULTS: The median follow up for the entire group was 38 months (range 7-64 months). The disease sites involved neck masses in patients with oropharynx (39), larynx (5), carcinoma unknown primary (5), and hypopharynx carcinoma (2). Concurrent chemotherapy and cetuximab were used in 41 and 1 patient(s), respectively. Recurrence was seen in 17 patients. At week 1 of RT, the support vector machine classifier resulted in the best performance, with accuracy and area under the curve (AUC) of 80% and 0.75, respectively. The accuracy and AUC improved to 82% and 0.81, respectively, at week 4 of treatment. CONCLUSION: QUS Delta-radiomics can predict higher risk of recurrence with reasonable accuracy in HNSCC.Clinical trial registration: clinicaltrials.gov.in identifier NCT03908684.
21
Radiomics: Images Are More than Pictures, They Are Data
Robert J. Gillies, Paul E. Kinahan, Hedvig Hricak · Radiology · 2015 · 8.3K citations